52North
About 52North
52North is a medical technology company on a mission to build innovative diagnostic and digital solutions to transform emergency care globally.
Founded in 2018 as a spin-out from the University of Cambridge, 52North develops in vitro diagnostic and digital solutions with patients and clinicians to make emergency care safer and more effective.
Its first product, Neutrocheck®, is a portable finger-prick blood test and app designed to identify immunosuppressed patients at risk of neutropenic sepsis and has been awarded breakthrough status by the UK Government in 2024.
They also develop a portable platform for cell measurement called Aster™, and a digital tool called ACORN™ for remote triaging and management of emergency cancer care needs.
The company has an award-winning multidisciplinary team based in Cambridge, UK, supported by venture funds from UK and US hospitals, including Meridian Health Ventures and Cedars-Sinai Intellectual Property Company, as well as partnerships with leading institutions like the University of Cambridge and Macmillan Cancer Support.
Leadership
Umaima Ahmad is the CEO and Founder, a qualified lawyer with extensive experience in governance, finance, and life sciences. Other key executives include Dr Rebecca Simmons (COO), Dr Mireia Crispin (CDO), Dr Saif Ahmad (CSMO), and Joe Neale (CTO).
Location and Contact
52North is headquartered at Ideaspace West, The Hauser Forum, 3 Charles Babbage Road, Cambridge, CB3 0GT, England.
Email contact: [email protected]
Careers
52North is an award-winning team of multidisciplinary experts building technological solutions for emergency care. Their teams include Clinical, Device R&D, Digital R&D, Quality & Regulatory, Market Access & Commercial, and Operations. They value execution, excellence, exemplary teamwork, and ethical innovation.
Currently, there are no open vacancies, but they welcome exceptional talent to contact [email protected].